ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 185 filers reported holding ASCENDIS PHARMA A/S in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $552,289 | +48.2% | 5,898 | +41.3% | 0.26% | +50.6% |
| Q2 2023 | $372,619 | -52.6% | 4,175 | -43.1% | 0.17% | -73.5% |
| Q1 2023 | $786,780 | -12.2% | 7,338 | 0.0% | 0.64% | +20.5% |
| Q4 2022 | $896,190 | -11.3% | 7,338 | -25.0% | 0.53% | -7.8% |
| Q3 2022 | $1,010,000 | +46.0% | 9,780 | +31.4% | 0.58% | +38.0% |
| Q2 2022 | $692,000 | -24.6% | 7,442 | -4.8% | 0.42% | -28.4% |
| Q1 2022 | $918,000 | -20.1% | 7,821 | -8.4% | 0.58% | -36.2% |
| Q4 2021 | $1,149,000 | -26.2% | 8,541 | -12.6% | 0.92% | -11.2% |
| Q3 2021 | $1,557,000 | +95.4% | 9,769 | +61.2% | 1.03% | +82.3% |
| Q2 2021 | $797,000 | +12.4% | 6,060 | +10.1% | 0.56% | +7.2% |
| Q1 2021 | $709,000 | -10.1% | 5,505 | +16.4% | 0.53% | +4.6% |
| Q4 2020 | $789,000 | +54.7% | 4,731 | +43.1% | 0.50% | +35.5% |
| Q3 2020 | $510,000 | +19.2% | 3,307 | +14.3% | 0.37% | +5.1% |
| Q2 2020 | $428,000 | – | 2,893 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |